Epstein-Barr virus and genetic risk variants as determinants of T-bet+ B cell-driven autoimmune diseases.

[1]  Hali Broncucia,et al.  Identification of an anergic BND cell–derived activated B cell population (BND2) in young-onset type 1 diabetes patients , 2023, The Journal of experimental medicine.

[2]  S. Gregory,et al.  An EBV-associated atypical B cell signature in clinically isolated syndrome is implicated in progression of multiple sclerosis , 2023, medRxiv.

[3]  J. Smolders,et al.  Selective emergence of antibody-secreting cells in the multiple sclerosis brain , 2023, EBioMedicine.

[4]  Vina Fan,et al.  Gammaherpesvirus infection drives age-associated B cells toward pathogenicity in EAE and MS , 2022, Science advances.

[5]  H. Scherer,et al.  Absence of Epstein-Barr virus DNA in anti-citrullinated protein antibody-expressing B cells of patients with rheumatoid arthritis , 2022, Arthritis Research & Therapy.

[6]  T. White,et al.  Multiple sclerosis risk variants influence the peripheral B‐cell compartment early in life in the general population , 2022, European journal of neurology.

[7]  M. Luftig,et al.  Epstein-Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes in vitro , 2022, Frontiers in Immunology.

[8]  C. Münz,et al.  Altered Immune Response to the Epstein–Barr Virus as a Prerequisite for Multiple Sclerosis , 2022, Cells.

[9]  R. Scofield,et al.  Polygenic autoimmune disease risk alleles impacting B cell tolerance act in concert across shared molecular networks in mouse and in humans , 2022, Frontiers in Immunology.

[10]  P. Lieberman,et al.  Epstein–Barr virus and multiple sclerosis , 2022, Nature reviews. Microbiology.

[11]  M. Luftig,et al.  Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein-Barr virus infection. , 2022, Cell reports.

[12]  J. Casanova,et al.  Human T-bet governs the generation of a distinct subset of CD11chighCD21low B cells , 2022, Science Immunology.

[13]  Lucas E. Wange,et al.  EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus–infected B cells , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[14]  U. Boschert,et al.  Human T-bet+ B cell development is associated with BTK activity and suppressed by evobrutinib , 2022, JCI insight.

[15]  M. Horwitz,et al.  Age-associated B cells in autoimmune diseases , 2022, Cellular and Molecular Life Sciences.

[16]  A. Bozec,et al.  Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways , 2022, Annals of the Rheumatic Diseases.

[17]  A. Sawalha,et al.  The lupus susceptibility allele DRB1*03:01 encodes a disease-driving epitope , 2022, Communications Biology.

[18]  A. Garyfallos,et al.  Involvement of age-associated B cells in EBV-triggered autoimmunity , 2022, Immunologic Research.

[19]  Y. Ye,et al.  Age-associated B cells indicate disease activity in rheumatoid arthritis. , 2022, Cellular immunology.

[20]  M. Horwitz,et al.  Age-associated B cells are long-lasting effectors that restrain reactivation of latent γHV68 , 2022, bioRxiv.

[21]  Timothy J. Peters,et al.  STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological dysregulation of NKG2Dhi CD8 killer T cells , 2022, bioRxiv.

[22]  A. Damasceno,et al.  Cytotoxic B Cells in Relapsing-Remitting Multiple Sclerosis Patients , 2022, Frontiers in Immunology.

[23]  O. Boyman,et al.  Systematic Review of Safety and Efficacy of Second- and Third-Generation CD20-Targeting Biologics in Treating Immune-Mediated Disorders , 2022, Frontiers in Immunology.

[24]  S. Elledge,et al.  Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis , 2022, Science.

[25]  A. Perl,et al.  Adenosine receptor 2a agonists target mouse CD11c+T-bet+ B cells in infection and autoimmunity , 2022, Nature communications.

[26]  N. Hattori,et al.  Dysregulated B cell differentiation towards antibody-secreting cells in neuromyelitis optica spectrum disorder , 2022, Journal of Neuroinflammation.

[27]  Timothy J. Peters,et al.  Overactive STAT3 drives accumulation of disease-associated CD21low B cells , 2021, bioRxiv.

[28]  M. Wampole,et al.  Bruton’s Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures , 2021, Frontiers in Immunology.

[29]  J. Casanova,et al.  The expansion of human T-bethighCD21low B cells is T cell dependent , 2021, Science Immunology.

[30]  D. Absher,et al.  STAT3-mediated allelic imbalance of novel genetic variant rs1047643 and B cell specific super-enhancer in association with systemic lupus erythematosus , 2021, bioRxiv.

[31]  J. Holoshitz,et al.  The Cusp theory: is there more to HLA-disease association? , 2021, Rheumatology.

[32]  Aaron M. Rosenfeld,et al.  Altered function and differentiation of age-associated B cells contribute to the female bias in lupus mice , 2021, Nature Communications.

[33]  Q. Lu,et al.  A novel humanized cutaneous lupus erythematosus mouse model mediated by IL-21-induced age-associated B cells. , 2021, Journal of autoimmunity.

[34]  K. Brown,et al.  Latent gammaherpesvirus exacerbates arthritis through modification of age-associated B cells , 2021, eLife.

[35]  Maxim N. Artyomov,et al.  Heterogeneity of meningeal B cells reveals a lymphopoietic niche at the CNS borders , 2021, Science.

[36]  P. Lieberman,et al.  Epigenetic Plasticity Enables CNS-Trafficking of EBV-infected B Lymphocytes , 2021, PLoS pathogens.

[37]  K. Tarte,et al.  Mass Cytometry Identifies Expansion of T-bet+ B Cells and CD206+ Monocytes in Early Multiple Sclerosis , 2021, Frontiers in Immunology.

[38]  M. Hertl,et al.  Detection of autoreactive CD4+ T cells by MHC class II multimers in HLA-linked human autoimmune diseases. , 2021, The Journal of clinical investigation.

[39]  P. Heeringa,et al.  B Cell Activation and Escape of Tolerance Checkpoints: Recent Insights from Studying Autoreactive B Cells , 2021, Cells.

[40]  B. Becher,et al.  Mass Cytometry of CSF Identifies an MS-Associated B-cell Population , 2021, Neurology: Neuroimmunology & Neuroinflammation.

[41]  L. Aira,et al.  Skin-homing regulatory B cells required for suppression of cutaneous inflammation. , 2021, The Journal of investigative dermatology.

[42]  M. Sahraian,et al.  Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis. , 2021, Multiple sclerosis and related disorders.

[43]  J. Guéry,et al.  Escape from X Chromosome Inactivation and the Female Predominance in Autoimmune Diseases , 2021, International journal of molecular sciences.

[44]  T. Matsushita,et al.  Suppression of IL-23-mediated psoriasis-like inflammation by regulatory B cells , 2021, Scientific Reports.

[45]  D. Tenen,et al.  Super-enhancers for RUNX3 are required for cell proliferation in EBV-infected B cell lines. , 2021, Gene.

[46]  T. Dörner,et al.  Toll-like receptor signalling in B cells during systemic lupus erythematosus , 2020, Nature Reviews Rheumatology.

[47]  M. Altfeld,et al.  Heterogeneous Escape from X Chromosome Inactivation Results in Sex Differences in Type I IFN Responses at the Single Human pDC Level , 2020, Cell Reports.

[48]  S. Brunak,et al.  Type I Interferons Promote Germinal Centers Through B Cell Intrinsic Signaling and Dendritic Cell Dependent Th1 and Tfh Cell Lineages , 2020, bioRxiv.

[49]  L. Staudt,et al.  Rewiring of B cell receptor signaling by Epstein–Barr virus LMP2A , 2020, Proceedings of the National Academy of Sciences.

[50]  A. Syvänen,et al.  Function of multiple sclerosis-protective HLA class I alleles revealed by genome-wide protein-quantitative trait loci mapping of interferon signalling , 2020, PLoS genetics.

[51]  M. V. van Zelm,et al.  The association of Epstein‐Barr virus infection with CXCR3+ B‐cell development in multiple sclerosis: impact of immunotherapies , 2020, European journal of immunology.

[52]  J. Smolders,et al.  Naive B cells in neuromyelitis optica spectrum disorders: impact of steroid use and relapses , 2020, Brain communications.

[53]  Irah L. King,et al.  Cbl and Cbl-b control the germinal center reaction by facilitating naive B cell antigen processing , 2020, The Journal of experimental medicine.

[54]  J. Smolders,et al.  B and T Cells Driving Multiple Sclerosis: Identity, Mechanisms and Potential Triggers , 2020, Frontiers in Immunology.

[55]  J. Lünemann,et al.  Attenuated immune control of Epstein–Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA‐DR15 , 2020, European journal of immunology.

[56]  J. Kaler,et al.  The Prevalence of Autoimmune Disorders in Women: A Narrative Review , 2020, Cureus.

[57]  Aaron M. Rosenfeld,et al.  The Transcription Factor T-bet Resolves Memory B Cell Subsets with Distinct Tissue Distributions and Antibody Specificities in Mice and Humans. , 2020, Immunity.

[58]  Daniel E. Miller,et al.  Epstein–Barr virus nuclear antigen 2 extensively rewires the human chromatin landscape at autoimmune risk loci , 2020, bioRxiv.

[59]  M. Cancro.  Age-Associated B Cells. , 2020, Annual review of immunology.

[60]  G. Stewart,et al.  The interaction of Multiple Sclerosis risk loci with Epstein-Barr virus phenotypes implicates the virus in pathogenesis , 2020, Scientific Reports.

[61]  Gavin Giovannoni,et al.  Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies , 2019, Trends in Molecular Medicine.

[62]  C. Syrett,et al.  When the balance is broken: X‐linked gene dosage from two X chromosomes and female‐biased autoimmunity , 2019, Journal of leukocyte biology.

[63]  Simon C. Potter,et al.  Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility , 2019, Science.

[64]  Huji Xu,et al.  Excessive CD11c+Tbet+ B cells promote aberrant TFH differentiation and affinity-based germinal center selection in lupus , 2019, Proceedings of the National Academy of Sciences.

[65]  I. Mårtensson,et al.  CD21−/low B cells associate with joint damage in rheumatoid arthritis patients , 2019, Scandinavian journal of immunology.

[66]  D. Kitamura,et al.  The quantity of CD40 signaling determines the differentiation of B cells into functionally distinct memory cell subsets , 2019, eLife.

[67]  H. D. de Vries,et al.  Induction of brain‐infiltrating T‐bet–expressing B cells in multiple sclerosis , 2019, Annals of neurology.

[68]  Nir Hacohen,et al.  The immune cell landscape in kidneys of patients with lupus nephritis , 2019, Nature Immunology.

[69]  Christopher D. Scharer,et al.  IFNγ induces epigenetic programming of human T-bethi B cells and promotes TLR7/8 and IL-21 induced differentiation , 2019, bioRxiv.

[70]  D. Arnold,et al.  Placebo-Controlled Trial of an Oral BTK Inhibitor in Multiple Sclerosis. , 2019, The New England journal of medicine.

[71]  E. Meffre,et al.  Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. , 2019, Brain : a journal of neurology.

[72]  G. Stewart,et al.  Evidence from genome wide association studies implicates reduced control of Epstein-Barr virus infection in multiple sclerosis susceptibility , 2019, Genome medicine.

[73]  M. Cancro,et al.  T-bet+ B cells: A common denominator in protective and autoreactive antibody responses? , 2019, Current opinion in immunology.

[74]  L. Looger,et al.  Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians , 2019, PLoS genetics.

[75]  M. Cancro,et al.  T‐bet+ memory B cells: Generation, function, and fate , 2019, Immunological reviews.

[76]  Shiliang Ma,et al.  B Cell Dysfunction Associated With Aging and Autoimmune Diseases , 2019, Front. Immunol..

[77]  O. Silvennoinen,et al.  Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases , 2019, BioDrugs.

[78]  M. Khademi,et al.  B cell alterations during BAFF inhibition with belimumab in SLE , 2018, EBioMedicine.

[79]  J. Gudjonsson,et al.  Sex bias in autoimmunity , 2018, Current opinion in rheumatology.

[80]  Xuetao Cao,et al.  Phosphorylation-Mediated IFN-γR2 Membrane Translocation Is Required to Activate Macrophage Innate Response , 2018, Cell.

[81]  Huixia Wu,et al.  The risk of systemic lupus erythematosus associated with Epstein–Barr virus infection: a systematic review and meta-analysis , 2018, Clinical and Experimental Medicine.

[82]  Vaishali R. Moulton.  Sex Hormones in Acquired Immunity and Autoimmune Disease , 2018, Front. Immunol..

[83]  G. Gibson,et al.  Distinct Effector B Cells Induced by Unregulated Toll‐like Receptor 7 Contribute to Pathogenic Responses in Systemic Lupus Erythematosus , 2018, Immunity.

[84]  Radleigh G. Santos,et al.  Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis , 2018, Cell.

[85]  Cameron S. Osborne,et al.  Enhancer control of miR-155 expression in Epstein-Barr virus infected B cells , 2018, bioRxiv.

[86]  Y. Kawasawa,et al.  B-Cell-Intrinsic Type 1 Interferon Signaling Is Crucial for Loss of Tolerance and the Development of Autoreactive B Cells , 2018, Cell reports.

[87]  D. Al-Sadeq,et al.  Epstein–Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update , 2018, Front. Oncol..

[88]  S. Rahman,et al.  IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet+ B cells in SLE , 2018, Nature Communications.

[89]  A. Bar-Or,et al.  Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis , 2018, Neurology.

[90]  M. Rovaris,et al.  HLA alleles modulate EBV viral load in multiple sclerosis , 2018, Journal of Translational Medicine.

[91]  R. Jessberger,et al.  Regulation of Age-associated B cells by IRF5 in systemic autoimmunity , 2018, Nature Immunology.

[92]  Daniel E. Miller,et al.  Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity , 2018, Nature Genetics.

[93]  A. Canivet,et al.  TLR7 escapes X chromosome inactivation in immune cells , 2018, Science Immunology.

[94]  M. Ban,et al.  Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells , 2018, Brain : a journal of neurology.

[95]  E. A. Mills,et al.  Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment , 2017, Autoimmunity Highlights.

[96]  K. Tarte,et al.  IL-2 imprints human naive B cell fate towards plasma cell through ERK/ELK1-mediated BACH2 repression , 2017, Nature Communications.

[97]  P. Marrack,et al.  T-bet expressing B cells - Novel target for autoimmune therapies? , 2017, Cellular immunology.

[98]  E. Kieff,et al.  The Epstein-Barr Virus Regulome in Lymphoblastoid Cells. , 2017, Cell host & microbe.

[99]  Lingling Wu,et al.  T-bet+CD11c+ B cells are critical for antichromatin immunoglobulin G production in the development of lupus , 2017, Arthritis Research & Therapy.

[100]  Marjolein J. W. de Bruijn,et al.  Enhanced Bruton's Tyrosine Kinase Activity in Peripheral Blood B Lymphocytes From Patients With Autoimmune Disease , 2017, Arthritis & rheumatology.

[101]  H. Eibel,et al.  High SYK Expression Drives Constitutive Activation of CD21low B Cells , 2017, The Journal of Immunology.

[102]  P. Marrack,et al.  B cells expressing the transcription factor T-bet drive lupus-like autoimmunity , 2017, The Journal of clinical investigation.

[103]  M. Cancro,et al.  A TLR9-dependent checkpoint governs B cell responses to DNA-containing antigens , 2017, The Journal of clinical investigation.

[104]  Cisca Wijmenga,et al.  The MHC locus and genetic susceptibility to autoimmune and infectious diseases , 2017, Genome Biology.

[105]  Joseph H. Marcus,et al.  Overexpression of the Cytokine BAFF and Autoimmunity Risk , 2017, The New England journal of medicine.

[106]  M. Ostrowski,et al.  T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response. , 2017, JCI insight.

[107]  X. Zuo,et al.  A genome-wide association study identifies six novel risk loci for primary biliary cholangitis , 2022 .

[108]  C. Mackay,et al.  c-Myb Regulates the T-Bet-Dependent Differentiation Program in B Cells to Coordinate Antibody Responses. , 2017, Cell reports.

[109]  Genita Metzler,et al.  Altered B cell signalling in autoimmunity , 2017, Nature Reviews Immunology.

[110]  T. Kurosaki,et al.  The transcription factor Foxo1 controls germinal center B cell proliferation in response to T cell help , 2017, The Journal of experimental medicine.

[111]  D. M. van der Heijde,et al.  Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis , 2017, The New England journal of medicine.

[112]  Bernhard Hemmer,et al.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis , 2017, The New England journal of medicine.

[113]  J. Tobias,et al.  Age-Associated B Cells Express a Diverse Repertoire of VH and Vκ Genes with Somatic Hypermutation , 2017, The Journal of Immunology.

[114]  E. Kieff,et al.  Epstein–Barr virus super-enhancer eRNAs are essential for MYC oncogene expression and lymphoblast proliferation , 2016, Proceedings of the National Academy of Sciences.

[115]  N. Hellings,et al.  Age-Associated B Cells with Proinflammatory Characteristics Are Expanded in a Proportion of Multiple Sclerosis Patients , 2016, The Journal of Immunology.

[116]  WangJinjing,et al.  T-bet-Expressing B Cells Are Positively Associated with Crohn's Disease Activity and Support Th1 Inflammation , 2016 .

[117]  Fredrick R. Schumacher,et al.  Modeling disease risk through analysis of physical interactions between genetic variants within chromatin regulatory circuitry , 2016, Nature Genetics.

[118]  E. Wherry,et al.  Cutting Edge: IL-4, IL-21, and IFN-γ Interact To Govern T-bet and CD11c Expression in TLR-Activated B Cells , 2016, The Journal of Immunology.

[119]  E. Meffre,et al.  PTPN22 inhibition resets defective human central B cell tolerance , 2016, Science Immunology.

[120]  M. V. van Zelm,et al.  B-Cell Dysregulation in Crohn's Disease Is Partially Restored with Infliximab Therapy , 2016, PloS one.

[121]  T. Kurosaki,et al.  Regulated selection of germinal-center cells into the memory B cell compartment , 2016, Nature Immunology.

[122]  M. Shlomchik,et al.  Continuous inhibitory signaling by both SHP-1 and SHIP-1 pathways is required to maintain unresponsiveness of anergic B cells , 2016, The Journal of experimental medicine.

[123]  D. Rawlings,et al.  B cell IFN-γ receptor signaling promotes autoimmune germinal centers via cell-intrinsic induction of BCL-6 , 2016, The Journal of experimental medicine.

[124]  F. Borrego,et al.  Fc Receptor–like 5 Expression Distinguishes Two Distinct Subsets of Human Circulating Tissue–like Memory B Cells , 2016, The Journal of Immunology.

[125]  Y. Kochi.  Genetics of autoimmune diseases: perspectives from genome-wide association studies. , 2016, International immunology.

[126]  M. Atchison,et al.  Unusual maintenance of X chromosome inactivation predisposes female lymphocytes for increased expression from the inactive X , 2016, Proceedings of the National Academy of Sciences.

[127]  Kyoung-Jae Won,et al.  EBNA2 Drives Formation of New Chromosome Binding Sites and Target Genes for B-Cell Master Regulatory Transcription Factors RBP-jκ and EBF1 , 2016, PLoS pathogens.

[128]  M. Shlomchik,et al.  Requirement for Transcription Factor Ets1 in B Cell Tolerance to Self-Antigens , 2015, The Journal of Immunology.

[129]  Ivan V. Gregoretti,et al.  Diversity, cellular origin and autoreactivity of antibody-secreting cell expansions in acute Systemic Lupus Erythematosus , 2015, Nature Immunology.

[130]  P. Marrack,et al.  TLR7, IFNγ, and T-bet: their roles in the development of ABCs in female-biased autoimmunity. , 2015, Cellular immunology.

[131]  A. Betz,et al.  The Novel Kinase Inhibitor PRT062070 (Cerdulatinib) Demonstrates Efficacy in Models of Autoimmunity and B-Cell Cancer , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[132]  P. Lipsky,et al.  Increased Frequency of a Unique Spleen Tyrosine Kinase Bright Memory B Cell Population in Systemic Lupus Erythematosus , 2014, Arthritis & rheumatology.

[133]  M. Daly,et al.  Genetic and Epigenetic Fine-Mapping of Causal Autoimmune Disease Variants , 2014, Nature.

[134]  L. Hutt-Fletcher,et al.  Epstein-Barr Virus Glycoprotein gB and gHgL Can Mediate Fusion and Entry in trans, and Heat Can Act as a Partial Surrogate for gHgL and Trigger a Conformational Change in gB , 2014, Journal of Virology.

[135]  Z. Zhou,et al.  Assembly and Architecture of the EBV B Cell Entry Triggering Complex , 2014, PLoS pathogens.

[136]  P. Mccombe,et al.  Gender differences in autoimmune disease , 2014, Frontiers in Neuroendocrinology.

[137]  A. Satterthwaite,et al.  A Balance between B Cell Receptor and Inhibitory Receptor Signaling Controls Plasma Cell Differentiation by Maintaining Optimal Ets1 Levels , 2014, The Journal of Immunology.

[138]  P. Gaffney,et al.  Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. , 2014, American journal of human genetics.

[139]  S. Tangye,et al.  Cytokine-Mediated Regulation of Plasma Cell Generation: IL-21 Takes Center Stage , 2014, Front. Immunol..

[140]  J. Casanova,et al.  IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. , 2013, Blood.

[141]  J. Casanova,et al.  Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells , 2013, The Journal of experimental medicine.

[142]  M. Carrington,et al.  Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects , 2013, PLoS genetics.

[143]  L. Hurst,et al.  Genes That Escape X-Inactivation in Humans Have High Intraspecific Variability in Expression, Are Associated with Mental Impairment but Are Not Slow Evolving , 2013, Molecular biology and evolution.

[144]  P. Marrack,et al.  T-box transcription factor T-bet, a key player in a unique type of B-cell activation essential for effective viral clearance , 2013, Proceedings of the National Academy of Sciences.

[145]  L. Davis,et al.  SLE Peripheral Blood B Cell, T Cell and Myeloid Cell Transcriptomes Display Unique Profiles and Each Subset Contributes to the Interferon Signature , 2013, PloS one.

[146]  D. Hafler,et al.  Specific peripheral B cell tolerance defects in patients with multiple sclerosis. , 2013, The Journal of clinical investigation.

[147]  R. Moon,et al.  A disease-associated PTPN22 variant promotes systemic autoimmunity in murine models. , 2013, The Journal of clinical investigation.

[148]  J. Cambier.  Autoimmunity risk alleles: hotspots in B cell regulatory signaling pathways. , 2013, The Journal of clinical investigation.

[149]  D. Cantrell,et al.  The BAFF Receptor Transduces Survival Signals by Co-opting the B Cell Receptor Signaling Pathway , 2013, Immunity.

[150]  P. Marrack,et al.  TLR7 drives accumulation of ABCs and autoantibody production in autoimmune-prone mice , 2012, Immunologic Research.

[151]  Toshihide Kobayashi,et al.  Role for Phospholipid Flippase Complex of ATP8A1 and CDC50A Proteins in Cell Migration* , 2012, The Journal of Biological Chemistry.

[152]  E. Coccia,et al.  Epstein–Barr virus persistence and infection of autoreactive plasma cells in synovial lymphoid structures in rheumatoid arthritis , 2012, Annals of the rheumatic diseases.

[153]  J. Lünemann,et al.  Persistence of Epstein-Barr Virus in Self-Reactive Memory B Cells , 2012, Journal of Virology.

[154]  B. Arnulf,et al.  The Ets-1 transcription factor is required for Stat1-mediated T-bet expression and IgG2a class switching in mouse B cells. , 2012, Blood.

[155]  G. Nienhaus,et al.  Human B cells differentiate into granzyme B‐secreting cytotoxic B lymphocytes upon incomplete T‐cell help , 2012, Immunology and cell biology.

[156]  L. Criswell,et al.  Emerging patterns of genetic overlap across autoimmune disorders , 2012, Genome Medicine.

[157]  Robert M. Plenge,et al.  Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis , 2011, Nature Genetics.

[158]  H. Lassmann,et al.  Epstein–Barr virus in the multiple sclerosis brain: a controversial issue—report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria , 2011, Brain : a journal of neurology.

[159]  P. Marrack,et al.  Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c⁺ B-cell population is important for the development of autoimmunity. , 2011, Blood.

[160]  Kasper Lage,et al.  Pervasive Sharing of Genetic Effects in Autoimmune Disease , 2011, PLoS genetics.

[161]  A. Davidson,et al.  BAFF and selection of autoreactive B cells. , 2011, Trends in immunology.

[162]  K. Peterson,et al.  TLR7 and TLR9 trigger distinct neuroinflammatory responses in the CNS. , 2011, The American journal of pathology.

[163]  D. Iliopoulos,et al.  Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression , 2011, Annals of the rheumatic diseases.

[164]  Kenneth M. Murphy,et al.  Batf controls the global regulators of class switch recombination in both B and T cells , 2011, Nature Immunology.

[165]  M. Tardieu,et al.  Interferon-Alpha Triggers B Cell Effector 1 (Be1) Commitment , 2011, PloS one.

[166]  Yonggang Sha,et al.  B Cells as a Therapeutic Target for IFN-β in Relapsing–Remitting Multiple Sclerosis , 2011, The Journal of Immunology.

[167]  M. Cancro,et al.  A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. , 2011, Blood.

[168]  N. Raab-Traub,et al.  Epstein-Barr Virus LMP1 Activates EGFR, STAT3, and ERK through Effects on PKCδ , 2011, Journal of Virology.

[169]  Charles Peterfy,et al.  An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents. , 2011, Arthritis and rheumatism.

[170]  M. Genovese,et al.  An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. , 2010, The New England journal of medicine.

[171]  M. Colonna,et al.  Type I IFN enhances follicular B cell contribution to the T cell–independent antibody response , 2010, The Journal of experimental medicine.

[172]  A. Ascherio,et al.  Primary infection with the Epstein‐Barr virus and risk of multiple sclerosis , 2010, Annals of neurology.

[173]  Philippa Marrack,et al.  Genetic and hormonal factors in female-biased autoimmunity. , 2010, Autoimmunity reviews.

[174]  Ryan M. O’Connell,et al.  Inositol phosphatase SHIP1 is a primary target of miR-155 , 2009, Proceedings of the National Academy of Sciences.

[175]  P. Gaffney,et al.  Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[176]  Michael R. Johnson,et al.  Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. , 2009, Human molecular genetics.

[177]  M. Cancro,et al.  BAFF and the plasticity of peripheral B cell tolerance. , 2008, Current opinion in immunology.

[178]  K. Rajewsky,et al.  LMP1 signaling can replace CD40 signaling in B cells in vivo and has unique features of inducing class-switch recombination to IgG1. , 2008, Blood.

[179]  J. Minárovits,et al.  Regulation and dysregulation of Epstein–Barr virus latency: Implications for the development of autoimmune diseases , 2008, Autoimmunity.

[180]  R. Reynolds,et al.  Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain , 2007, The Journal of experimental medicine.

[181]  Feifei Zhao,et al.  Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor. , 2007, Clinical immunology.

[182]  C. Cunningham-Rundles,et al.  CD40 ligand and MHC class II expression are essential for human peripheral B cell tolerance , 2007, The Journal of experimental medicine.

[183]  J. Mrázek,et al.  Epstein-Barr Virus-Encoded Latent Membrane Protein 1 (LMP1) Induces the Expression of the Cellular MicroRNA miR-146a , 2007, RNA biology.

[184]  R. Hardy,et al.  Control of the B cell-intrinsic tolerance programs by ubiquitin ligases Cbl and Cbl-b. , 2007, Immunity.

[185]  R. Straub,et al.  Estrogens and Autoimmune Diseases , 2006, Annals of the New York Academy of Sciences.

[186]  A. Ascherio,et al.  Infectious mononucleosis and risk for multiple sclerosis: A meta‐analysis , 2006, Annals of neurology.

[187]  H. Eibel,et al.  A new CD21low B cell population in the peripheral blood of patients with SLE. , 2004, Clinical immunology.

[188]  P. Emery,et al.  Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. , 2004, The New England journal of medicine.

[189]  S. Pierce,et al.  Cbl-b Negatively Regulates B Cell Antigen Receptor Signaling in Mature B Cells through Ubiquitination of the Tyrosine Kinase Syk , 2003, The Journal of experimental medicine.

[190]  Nathalie Balandraud,et al.  Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: accurate quantification using real-time polymerase chain reaction. , 2003, Arthritis and rheumatism.

[191]  L. Young,et al.  Epstein-Barr Virus Latent Membrane Protein 1 (LMP1) Activates the Phosphatidylinositol 3-Kinase/Akt Pathway to Promote Cell Survival and Induce Actin Filament Remodeling* , 2003, The Journal of Biological Chemistry.

[192]  S. Szabo,et al.  T-bet regulates IgG class switching and pathogenic autoantibody production , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[193]  R. Longnecker,et al.  Epstein-Barr Virus Latent Membrane Protein 2a (Lmp2a) Employs the Slp-65 Signaling Module , 2001, The Journal of experimental medicine.

[194]  M. Ueffing,et al.  Latent membrane protein 1 of Epstein–Barr virus interacts with JAK3 and activates STAT proteins , 1999, The EMBO journal.

[195]  G. Ebers.  Interferon β treatment for multiple sclerosis , 1999, The Lancet.

[196]  S. Anderson,et al.  Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. , 1998, Immunity.

[197]  D. Thorley-Lawson,et al.  EBV persistence in memory B cells in vivo. , 1998, Immunity.

[198]  Qingxue Li,et al.  Epstein-Barr Virus Uses Different Complexes of Glycoproteins gH and gL To Infect B Lymphocytes and Epithelial Cells , 1998, Journal of Virology.

[199]  J. Harley,et al.  An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. , 1997, The Journal of clinical investigation.

[200]  J. Todd,et al.  HLA-DQβ gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus , 1987, Nature.

[201]  E. Kieff,et al.  Epstein-barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis , 1987, Cell.

[202]  E. Tan,et al.  Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. , 1981, The Journal of clinical investigation.

[203]  T. Kanda.  EBV-Encoded Latent Genes. , 2018, Advances in experimental medicine and biology.

[204]  J. Holoshitz,et al.  MHC molecules in health and disease: At the cusp of a paradigm shift. , 2011, Self/nonself.

[205]  I. Sanz,et al.  Altered B cell receptor signaling in human systemic lupus erythematosus. , 2009, Autoimmunity reviews.

[206]  A. Zhernakova,et al.  Detecting shared pathogenesis from the shared genetics of immune-related diseases , 2009, Nature Reviews Genetics.

[207]  R. Reynolds,et al.  Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. , 2007, Brain : a journal of neurology.

[208]  S. Ness,et al.  Point mutations in v-Myb disrupt a cyclophilin-catalyzed negative regulatory mechanism. , 1998, Molecular cell.